Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
Ladenstein R., Pötschger U., Pearson A.D., Brock P., Luksch R., Castel V., Yaniv I., Papadakis V., Laureys G., Malis J. et al., 2017/04. The Lancet. Oncology, 18 (4) pp. 500-514. Peer-reviewed.
ici le détail